+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

GSK plc (GSK) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 113 Pages
  • May 2026
  • GlobalData
  • ID: 5649247
GSK plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GSK plc (GSK) is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines. The company's major products encompass specialty medicines, vaccines, and general medicines targeting therapeutic areas such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology, and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health, and gastrointestinal diseases. GSK’s vaccine portfolio covers various diseases, including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles, and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians, and other groups globally. GSK is headquartered in London, England, the UK.

GSK plc Key Recent Developments

  • May 12, 2026: Artios and GSK Collaborate to Evaluate Alnodesertib With Risvutatug Rezetecan in Gastrointestinal Tumors
  • May 07, 2026: Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
  • May 06, 2026: GSK Presents Latest Respiratory Research to Advance Patient Care at ATS 2026
  • Apr 29, 2026: GSK Delivers Strong Q1 Performance and Start to 2026

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • GSK plc - Key Facts
  • GSK plc - Key Employees
  • GSK plc - Key Employee Biographies
  • GSK plc - Major Products and Services
  • GSK plc - History
  • GSK plc - Company Statement
  • GSK plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • GSK plc - Business Description
  • Business Segment: Commercial Operations
  • Overview
  • Performance
  • Business Segment: Total R&D
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: International
  • Performance
  • Geographical Segment: US
  • Performance
  • R&D Overview
  • GSK plc - Corporate Strategy
  • GSK plc - SWOT Analysis
  • SWOT Analysis - Overview
  • GSK plc - Strengths
  • GSK plc - Weaknesses
  • GSK plc - Opportunities
  • GSK plc - Threats
  • GSK plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • GSK plc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • GSK plc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • GSK plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 12, 2026: Artios and GSK Collaborate to Evaluate Alnodesertib With Risvutatug Rezetecan in Gastrointestinal Tumors
  • May 07, 2026: Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
  • May 06, 2026: GSK Presents Latest Respiratory Research to Advance Patient Care at ATS 2026
  • Apr 29, 2026: GSK Delivers Strong Q1 Performance and Start to 2026
  • Apr 21, 2026: Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects with Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
  • Apr 20, 2026: Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
  • Apr 15, 2026: Cancer Dependency Map Consortium launches Phase 3 to accelerate next-generation therapeutics
  • Mar 19, 2026: GSK, University of Oxford and Imperial College London Launch Centre to Build Digital Twins of Organs
  • Mar 11, 2026: FDA approves GSK’s Wellcovorin for cerebral folate deficiency
  • Mar 09, 2026: GSK and Alfasigma Agree Worldwide Rights for Linerixibat
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • GSK plc, Key Facts
  • GSK plc, Key Employees
  • GSK plc, Key Employee Biographies
  • GSK plc, Major Products and Services
  • GSK plc, History
  • GSK plc, Other Locations
  • GSK plc, Subsidiaries
  • GSK plc, Joint Venture
  • GSK plc, Key Competitors
  • GSK plc, Ratios based on current share price
  • GSK plc, Annual Ratios
  • GSK plc, Interim Ratios
  • GSK plc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • GSK plc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • GSK plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • GSK plc, Performance Chart (2021-2025)
  • GSK plc, Ratio Charts
  • GSK plc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • GSK plc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Merck KGaA
  • Sanofi
  • Pfizer Inc
  • Gilead Sciences Inc
  • Bayer AG
  • Amgen Inc
  • Novartis AG
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • CSL Ltd
  • Eli Lilly and Co
  • Takeda Pharmaceutical Co Ltd
  • Moderna Inc
  • Bristol-Myers Squibb Co
  • AstraZeneca Plc
  • AbbVie Inc